ストックスクリーナーアプリを入手
9.78
6.19%
0.57
前日終値:
$9.21
開ける：
$9.31
24時間の取引高:
1.76M
Relative Volume:
0.97
時価総額：
$1.65B
収益：
$68.56M
当期純損益:
$-437.99M
株価収益率:
-3.0911
EPS:
-3.1639
ネットキャッシュフロー:
$-396.61M
1週間 パフォーマンス:
+5.84%
1か月 パフォーマンス:
+3.82%
6か月 パフォーマンス:
+29.37%
1年 パフォーマンス:
+123.29%
1日の値動き範囲:
$9.305
$9.86
1週間の範囲:
$9.025
$10.08
52週間の値動き範囲:
$4.35
$11.66
Vir Biotechnology Inc Stock (VIR) Company Profile
名前
Vir Biotechnology Inc
セクター
電話
415-906-4324
住所
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
9.78 | 1.56B | 68.56M | -437.99M | -396.61M | -3.1639 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-24 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2025-09-03 | 開始されました | Evercore ISI | Outperform |
| 2025-08-27 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-09-08 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-03-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-02-21 | アップグレード | Goldman | Neutral → Buy |
| 2023-01-27 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | 開始されました | SVB Leerink | Outperform |
| 2022-09-09 | 開始されました | Morgan Stanley | Underweight |
| 2022-03-03 | アップグレード | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-09-22 | ダウングレード | Goldman | Buy → Neutral |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-01-27 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-05 | 開始されました | BofA Securities | Buy |
| 2020-09-14 | アップグレード | Goldman | Neutral → Buy |
| 2020-09-11 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-08-20 | 開始されました | Needham | Buy |
| 2020-03-19 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-03-13 | ダウングレード | Goldman | Buy → Neutral |
| 2020-02-27 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-11-14 | 開始されました | Robert W. Baird | Neutral |
| 2019-11-05 | 開始されました | Barclays | Overweight |
| 2019-11-05 | 開始されました | Cowen | Outperform |
| 2019-11-05 | 開始されました | Goldman | Buy |
| 2019-11-05 | 開始されました | JP Morgan | Overweight |
すべてを表示
Vir Biotechnology Inc (VIR) 最新ニュース
Vir Biotechnology (NASDAQ: VIR) ex-officer files notice for potential $245K stock sale - Stock Titan
Vir Biotechnology on Track for Record Winning Streak -- Data Talk - Bitget
Vir (VIR) Close and Levels: Adds 1.06% to Close at $9.49 in the Latest Reading; Key Levels: the $9.02 to $9.96 Range Remains in Focus in Latest TradingRevenue Weighted - vinanet.vn
The Bull Case For Vir Biotechnology (VIR) Could Change Following A Sudden Swing To Quarterly Profitability - Sahm
Vir Biotechnology’s Earnings Call Signals Data-Driven Momentum - TipRanks
VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership - Stocktwits
Vir Biotechnology (VIR) Climbs 2.67% to $9.24 as Trading Volume Picks UpETH Profile - vinanet.vn
Vir Biotechnology Stock Price Forecast. Should You Buy VIR? - StockInvest.us
Vir Biotechnology, Inc. (VIR) Stock Forecasts - Yahoo Finance
Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript - The Globe and Mail
Vir Biotechnology (VIR) director restructures 16,000-share holding with Alta Partners fund - Stock Titan
Equities Analysts Offer Predictions for VIR Q3 Earnings - marketbeat.com
Vir Biotechnology: Astellas Deal Pushes Cash Above $1 Billion And Extends Runway Into Second Half Of 2028 - Pulse 2.0
Vir Biotechnology (NASDAQ:VIR): What’s Driving Fresh Attention? - Kalkine Media
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? - Stocktwits
H.C. Wainwright reiterates Vir Biotechnology stock rating on trial progress By Investing.com - Investing.com Canada
Vir Biotechnology Inc (VIR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Vir Biotechnology (VIR) Receives a Buy from Bank of America Securities - The Globe and Mail
What Vir Biotechnology (VIR)'s Profit Swing But Earnings Miss Means For Shareholders - simplywall.st
Vir Biotechnology (NASDAQ:VIR) Stock Rating Upgraded by Wall Street Zen - MarketBeat
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $15 to $30 - Moomoo
Vir Biotechnology (VIR): State Street discloses 9.96M-share, 5.9% ownership position - Stock Titan
Understanding Momentum Shifts in (VIR) - Stock Traders Daily
Vir Biotechnology, Inc. Stock 12‑Month Price Target Cut to $21, Implies 140% Upside - TradingView
Vir Biotechnology Inc (VIR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vir Biotechnology, Inc. (VIR) Stock Analysis: Unpacking a 140% Potential Upside for Investors - DirectorsTalk Interviews
Vir Biotechnology, Inc. Stock 12‑Month Price Target Cut to $21.11, Implies 132% Upside - TradingView
Vir Biotechnology, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
VIR Looks 63.2% Undervalued on GF Value™ - GuruFocus
Vir Biotechnology Q2 Earnings Call Highlights - MarketBeat
Vir Biotechnology, Inc. Stock 12‑Month Price Target Cut to $21.33, Implies 134% Upside - TradingView
VIR SWOT Analysis: Financial Resilience Amidst Clinical Challenges Revealed in 10-Q Filing - GuruFocus
Vir Biotechnology Inc (VIR) (Q2 2026) Earnings Call Highlights: - GuruFocus
Vir Biotechnology Inc (VIR) (Q2 2026) Earnings Call Highlights: 88% HDV Cure Rate and a $1B ... - Yahoo Finance
Vir Biotechnology (NASDAQ:VIR) Jumps 10% on Q2 Beat and Astellas Collaboration - ChartMill
VIR Looks 62.9% Undervalued on GF Value™ Despite Unprofitable St - GuruFocus
Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates - Yahoo Finance
Earnings call transcript: Vir Biotechnology jumps on q2 2026 cash and data gains - Investing.com
Vir Biotechnology, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Is Vir Biotechnology Inc (VIR) Undervalued After Q2 Earnings? EP - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Posts Quarterly Earnings Results, Beats Estimates By $0.14 EPS - MarketBeat
Vir Biotechnology Q2 2026 slides: hepatitis delta, oncology gains - Investing.com
Vir Biotechnology (VIR) Releases Q2 2026 Earnings: Revenue and EPS Beat Estimates - Quiver Quantitative
Vir Biotechnology Inc. (VIR) Tops Q2 EPS by 14c - StreetInsider
Vir Biotechnology 2Q 2026: Revenue $238.95M, Net income $80.08M, EPS $0.47— 10-Q Summary - TradingView
Vir Biotechnology (NASDAQ: VIR) swings to profit on $239.3M Astellas deal - Stock Titan
Earnings Flash (VIR) Vir Biotechnology, Inc. Reports Q2 Revenue $238.9M - marketscreener.com
Vir Biotechnology Q2 revenue up, beats estimates on Astellas payment - TradingView
Vir Biotechnology posts $238.9M Q2 revenue, $80.1M net income; $1.01B cash runway into H2 2028 - TradingView
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results - marketscreener.com
Vir Biotechnology Inc (VIR) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
1.07%
大文字化:
|
ボリューム (24 時間):